Cerecor (CERC) Receiving Favorable Media Coverage, Study Shows

Headlines about Cerecor (NASDAQ:CERC) have trended positive recently, AlphaOne reports. AlphaOne, a division of Accern, ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cerecor earned a coverage optimism score of 0.31 on AlphaOne’s scale. AlphaOne also assigned news stories about the company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an impact on the company’s share price in the next several days.

Cerecor (NASDAQ:CERC) last announced its quarterly earnings results on Tuesday, May 9th. The company reported ($0.19) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.18. The business had revenue of $0.38 million for the quarter.

WARNING: This piece of content was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/05/20/cerecor-cerc-receives-daily-news-sentiment-score-of-0-31-updated.html.

In other Cerecor news, major shareholder Armistice Capital Master Fund purchased 450,000 shares of the company’s stock in a transaction that occurred on Thursday, May 11th. The shares were bought at an average cost of $0.73 per share, for a total transaction of $328,500.00. The purchase was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 6.70% of the company’s stock.

Cerecor Company Profile

Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

12 Month Chart for NASDAQ:CERC

Receive News & Ratings for Cerecor Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply